€0.58
Your prediction
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Financial data and news for Defence Therapeutics Inc.
sharewise wants to provide you with the best news and tools for Defence Therapeutics Inc., so we directly link to the best financial data sources.
Financials
News
EQS-News: DEFENCE RECEIVES NO OBJECTION LETTER FROM HEALTH CANADA FOR PHASE I TRIAL OF ITS ACCUM-002 (ACCUTOX) AS AN ANTI-CANCER MOLECULE IN PATIENTS WITH MELANOMA
EQS-News: DEFENCE’S ACCUTOX BOOSTS AND SYNERGIZES WITH IMMUNE CHECKPOINT INHIBITORS
EQS-News: DEFENCE’S ARM-X ANTI-CANCER VACCINE INHIBITS GROWTH OF PRE-ESTABLISHED OVARIAN CANCER RESULTING IN COMPLETE RESPONSES IN TREATED ANIMALS
EQS-News: DEFENCE’S CHIEF SCIENTIFIC OFFICER DR. MOUTIH RAFEI DISCUSSES THE ACCUM PLATFORM FOR CANCER TREATMENTS ON MONEY TALK RADIO WITH ELLIS MARTIN
EQS-News: DEFENCE TO PARTICIPATE TO 2024 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING ANNUAL MEETING IN TORONTO ON JUNE 11, 2024
EQS-News: DEFENCE’S ACCUTOX PUBLISHED IN THE PRESTIGIOUS JOURNAL OF TRANSLATIONAL MEDICINE ITS PEER STUDY WITH PRECLINICAL DATA ON ACCUTOX AS AN ANTI-CANCER MOLECULE
EQS-News: DEFENCE THERAPEUTICS STRENGTHENS AND EXPANDS GLOBAL PATENT PROTECTION ON KEY TECHNOLOGIES
EQS-News: PANCREACTIC CANCER: SUCCESFUL TRIAL AGAINST PANCREATIC CANCER WITH DEFENCE’S ARM-002 ANTI-CANCER VACCINE
EQS-News: DEFENCE’S ACCUTOX ANTI-CANCER ARM-002 VACCINE EXHIBITS POTENT ANTIGEN PRESENTATION
EQS-News: DEFENCE THERAPEUTICS SIGNS WITH GERMAN BASED FMS CONSULT GMBH FOR FINANCING STRATEGY TO SUPPORT DEFENCE PIPELINE GROWTH
EQS-News: ERFOLGE VON DEFENCE BEI SEINEM ACCUTOX®-ARM(TM)-VAKZIN ZUR KREBSBEKÄMPFUNG FÜHREN ZUR ENTWICKLUNG EINES WIRKUNGSVOLLEN ARM-002(TM)-KREBSIMPFSTOFFS DER ZWEITEN GENERATION
EQS-News: DEFENCE’S SUCCESSFUL RESULTS ON ITS ACCUTOX® ANTI-CANCER ARMTM VACCINE CREATES A POTENT SECOND-GENERATION ANTI-CANCER ARM-002TM VACCINE
EQS-News: DEFENCE THERAPEUTICS AWARDED BROAD U.S. PATENT COVERING ITS PIONEERING CANCER-KILLING ACCUTOX® TECHNOLOGY
Defence Receives No Objection Letter from Health Canada for Phase I Trial of its Accum-002 (Accutox) as an Anti-Cancer Molecule in Patients With Melanoma
Vancouver, BC, Canada, July 8th, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a Canadian biopharmaceutical company developing novel
Defence’s Chief Scientific Officer Dr. Moutih Rafei Discusses the Accum Platform for Cancer Treatments on Money Talk Radio with Ellis Martin
Vancouver, BC, Canada, June 17th, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a Canadian biopharmaceutical company developing novel
Defence to Participate in 2024 Society of Nuclear Medicine and Molecular Imaging Annual Meeting in Toronto on June 11, 2024
Vancouver, BC, Canada, June 10th, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a Canadian biopharmaceutical company developing novel
Defence's AccuTOX Published in the Prestigious Journal of Translational Medicine Its Peer Study with Preclinical Data on AccuTOX as an Anti-Cancer Molecule
Vancouver, BC, Canada, June 6th, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a Canadian biopharmaceutical company developing novel
Defence Therapeutics Strengthens and Expands Global Patent Protection on Key Technologies
Vancouver, BC, Canada, May 14, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a Canadian biopharmaceutical company developing novel
Pancreactic Cancer: Succesful Trial Against Pancreatic Cancer with Defence’s ARM-002 Anti-Cancer Vaccine
Vancouver, BC, Canada, May 1st, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a Canadian biopharmaceutical company developing novel
Defence’s AccuTOX Anti-Cancer ARM-002 Vaccine Exhibits Potent Antigen Presentation
Vancouver, BC, Canada, April 23rd, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a Canadian biopharmaceutical company developing novel
Defence Therapeutics Signs with German Based FMS Consult GmbH for Financing Strategy to Support Defence Pipeline Growth
Vancouver, BC, Canada, April 17th, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a Canadian biopharmaceutical company developing novel
Defence’s Successful Results on its AccuTOX® Anti-Cancer ArmTM Vaccine Creates a Potent Second-Generation Anti-Cancer Arm-002TM Vaccine
Vancouver, BC, Canada, March 26th, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a Canadian biotechnology company developing novel
Defence Therapeutics Awarded Broad U.S. Patent Covering its Pioneering Cancer-Killing Accutox® Technology
Vancouver, BC, Canada, March 4th, 2024 - Defence Therapeutics Inc. (“Defence” or the “Company”), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug